BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 38554489)

  • 1. Charge-switchable nanoparticles enhance Cancer immunotherapy based on mitochondrial dynamic regulation and immunogenic cell death induction.
    Zhao M; Li J; Liu J; Xu M; Ji H; Wu S; Chen D; Hu H
    J Control Release; 2021 Jul; 335():320-332. PubMed ID: 34062192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delicaflavone reactivates anti-tumor immune responses by abrogating monocytic myeloid cell-mediated immunosuppression.
    Li L; You W; Wang X; Zou Y; Yao H; Lan H; Lin X; Zhang Q; Chen B
    Phytomedicine; 2023 Jan; 108():154508. PubMed ID: 36332384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
    Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
    J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploiting the immune system in hepatic tumor targeting: Unleashing the potential of drugs, natural products, and nanoparticles.
    Hsu CY; Mustafa MA; Kumar A; Pramanik A; Sharma R; Mohammed F; Jawad IA; Mohammed IJ; Alshahrani MY; Ali Khalil NAM; Shnishil AT; Abosaoda MK
    Pathol Res Pract; 2024 Apr; 256():155266. PubMed ID: 38554489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting anticancer immunity in oral cancer: Drugs, products, and nanoparticles.
    Qin L; Wu J
    Environ Res; 2023 Dec; 239(Pt 1):116751. PubMed ID: 37507044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-associated Macrophages (TAMs) in Cancer Resistance; Modulation by Natural Products.
    Lafta HA; AbdulHussein AH; Al-Shalah SAJ; Alnassar YS; Mohammed NM; Akram SM; Qasim MT; Najafi M
    Curr Top Med Chem; 2023; 23(12):1104-1122. PubMed ID: 36722486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The exploitation of enzyme-based cancer immunotherapy.
    Chandan G; Saini AK; Kumari R; Chakrabarti S; Mittal A; Sharma AK; Saini RV
    Hum Cell; 2023 Jan; 36(1):98-120. PubMed ID: 36334180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy.
    Gaggero S; Witt K; Carlsten M; Mitra S
    Front Immunol; 2020; 11():621225. PubMed ID: 33584718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting of the tumor immune microenvironment by metformin.
    Wu Z; Zhang C; Najafi M
    J Cell Commun Signal; 2022 Sep; 16(3):333-348. PubMed ID: 34611852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulating the tumor immune microenvironment with nanoparticles: A sword for improving the efficiency of ovarian cancer immunotherapy.
    Xu T; Liu Z; Huang L; Jing J; Liu X
    Front Immunol; 2022; 13():1057850. PubMed ID: 36532066
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.